WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 584880
Description: NA 0345 is a SF 2370 derivative that produces a selective inhibition of the alpha 1-mediated PIE, probably through inhibition of the alpha 1-adrenoceptor-mediated activation of PKC.
MedKoo Cat#: 584880
Name: NA 0345
Chemical Formula: C27H26N4O3
Exact Mass: 454.2005
Molecular Weight: 454.53
Elemental Analysis: C, 71.35; H, 5.77; N, 12.33; O, 10.56
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: NA 0345; NA-0345; NA0345
IUPAC/Chemical Name: 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-10-((methylamino)methyl)-, (9S-(9alpha,10beta,12alpha))-
InChi Key: NCSMUKLSRPWCNB-RJNNFIAUSA-N
InChi Code: InChI=1S/C27H26N4O3/c1-27-9-4-10-30-19-5-3-6-21(32)24(19)23-18-13-29-12-17(18)22-16-8-7-15(34-27)11-20(16)31(27,33,14-28-2)26(22)25(23)30/h4-5,7-9,12-13,15,28,33H,3,6,10-11,14H2,1-2H3/b9-4-/t15-,27+/m1/s1
SMILES Code: O=C(CCC=C12)C1=C3C4=CN=CC4=C5C6=C3N2C/C=C\[C@@](O7)(C)N6(CNC)(O)C8=C5C=C[C@]7([H])C8
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 454.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Endoh M, Norota I, Takanashi M, Kasai H. Inotropic effects of staurosporine, NA 0345 and H-7, protein kinase C inhibitors, on rabbit ventricular myocardium: selective inhibition of the positive inotropic effect mediated by alpha 1-adrenoceptors. Jpn J Pharmacol. 1993 Sep;63(1):17-26. PubMed PMID: 8271527.
2: Souhrada M, Souhrada JF. The role of protein kinase-C in sensitization and antigen response of airway smooth muscle. Am Rev Respir Dis. 1989 Dec;140(6):1567-72. PubMed PMID: 2604287.
3: Endoh M. Cardiac alpha(1)-adrenoceptors that regulate contractile function: subtypes and subcellular signal transduction mechanisms. Neurochem Res. 1996 Feb;21(2):217-29. Review. PubMed PMID: 9182246.
4: Okagaki T, Ishikawa R, Kohama K. Inhibitory Ca(2+)-regulation of myosin light chain kinase in the lower eukaryote, Physarum polycephalum: role of a Ca(2+)-dependent inhibitory factor. Eur J Cell Biol. 1991 Oct;56(1):113-22. PubMed PMID: 1666040.
5: Hachisu M, Hiranuma T, Koyama M, Sezaki M. Antihypertensive compounds with potent protein kinases inhibitory activity. Life Sci. 1989;44(19):1351-62. PubMed PMID: 2765030.
6: Souhrada M, Souhrada JF. Inhibitory effect of staurosporine on protein kinase C stimulation of airway smooth muscle cells. Am Rev Respir Dis. 1993 Aug;148(2):425-30. PubMed PMID: 8342907.